Lenko Medical

Lenko Medical, headquartered in Shenzhen, China, specializes in high-pressure imaging technology and medical devices. The company focuses on enhancing the efficiency and safety of medical imaging processes through innovative solutions. Shenzhen Lenko Medical Technology Co. , Ltd.

was founded in 2024 and is engaged in the development of high-pressure imaging solutions. The company operates out of Shenzhen, China, and has a total of 1 deal recorded. The company's most recent deal occurred on January 15, 2026. The founder's history is not explicitly documented.

Shenzhen Lenko Medical Technology Co. , Ltd. specializes in high-pressure imaging and innovative medical devices, particularly the Nova UC3000, a three-channel peristaltic pump CT high-pressure injector, and related consumables like syringes and tubing for critical care applications. Their products meet the needs of healthcare professionals by ensuring precise fluid delivery during imaging, with adoption in over a hundred tertiary hospitals across China.

Lenko Medical is focused on expanding its reach into international markets within the high-pressure imaging equipment sector. Shenzhen Lenko Medical Technology Co. , Ltd. operates on a B2B model, generating revenue through sales of high-pressure injectors and consumables directly to hospitals and medical facilities.

Transactions are typically conducted through bulk purchase agreements or long-term contracts, with flagship products like the Nova UC3000 attracting significant interest from healthcare providers. The company is recognized in the medical device market, supported by certifications from national authorities and endorsements from leading medical institutions. In January 2026, Lenko Medical raised an undisclosed amount in Series A funding led by Bioching Capital, with participation from Guangdong Guocheng Biomedical Technology. The funding will strengthen Lenko's core technology platform, enhance their product pipeline, and support team development, reinforcing their competitive advantage in high-pressure contrast imaging.

The company aims to launch new products and expand into international markets by 2026, targeting regions with high demand for advanced medical imaging solutions.